UK behavioural investigations under Article 102 TFEU/Chapter II Competition Act—closed cases tracker
UK behavioural investigations under Article 102 TFEU/Chapter II Competition Act—closed cases tracker

The following Competition practice note provides comprehensive and up to date legal information covering:

  • UK behavioural investigations under Article 102 TFEU/Chapter II Competition Act—closed cases tracker
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

UK behavioural investigations under Article 102 TFEU/Chapter II Competition Act—closed cases tracker

The table lists completed CMA, OFT and sectoral regulator investigations since 2013 under Article 102 TFEU/Chapter II Competition Act 1998.

Note—only investigations that have been made public are included in this table.

For ongoing behavioural investigations, see UK behavioural investigations—ongoing cases tracker. For details of appeals, see UK competition appeals—ongoing cases tracker. For details of completed cases under Article 101 TFEU/Chapter I Competition Act 1998, see UK behavioural investigations under Article 101 TFEU/Chapter I Competition Act—closed cases tracker. For details of cases where the CMA has sought director disqualification, see UK competition director disqualifications—cases tracker.

2020

Case name and companies under investigationCompetition authorityIssues Latest development
Priadel

Essential Pharma

CMA

Alleged abuse of a dominant position through exclusionary practices

• Commitments accepted and case closed—18/12/2020
• Consultation on proposed commitments launched—24/11/2020
• Investigation opened—06/10/2020

Hand sanitiser products (50924)

CMA

Excessive and unfair prices

• Fourth case closed—03/09/2020
• Three cases closed—13/07/2020; one remains ongoing
• Four investigations opened—19/06/2020

2019

Case name and companies under investigationCompetition authorityIssues Latest development
Pharmaceutical sector: suspected anti-competitive agreements and conduct (50780)

Unknown

CMA

Potential abuse of a dominant position by various parties in relation to the supply of certain generic pharmaceutical products (note—also being investigated under Article 101 TFEU/Chapter I)

• Investigation closed—26/11/2019
• Decision to continue with investigation—July 2018

Popular documents